Differences in systemic inflammation between cigarette and biomass smoke-induced COPD

International Journal of COPD

Volumn 12, Issue , 2017, Pages 2639-2646

  Golpe, Rafael ^a   Martín Robles, Irene ^a   Sanjuán López, Pilar ^a   Pérez de Llano, Luis ^a   González Juanatey, Carlos ^b   López Campos, José L ^c,d   Arellano Orden, Elena ^d  

^a Respiratory Medicine Service   (Spain)

^b Hospital Universitario Lucus Augusti   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Biomass smoke; COPD; Cytokines; Inflammation; Smoking

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CIGARETTE SMOKE; FIBRINOGEN; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; NITRIC OXIDE; SPHINGOLIPID ACTIVATOR PROTEIN 2; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR; AUTACOID;

AGED; ARTICLE; BIOMASS; BIOMASS SMOKE; BLOOD CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; MALE; PROTEIN BLOOD LEVEL; SMOKE; SMOKING; BLOOD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; EXPOSURE; IMMUNOLOGY; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; UPREGULATION;

AGED; BIOMARKERS; BIOMASS; CROSS-SECTIONAL STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION MEDIATORS; INHALATION EXPOSURE; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKE; SMOKING; UP-REGULATION;

EID: 85029185936     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S141068     Document Type: Article

References (34)

1. Salvi S, Barnes PJ. Is exposure to biomass smoke the biggest risk factor for COPD globally? Chest. 2010;138:3-6.
2. Sood A, Petersen H, Blanchette CM, et al. Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. Am J Respir Crit Care Med. 2010;182(9):1098-1104.
3. Orozco-Levi M, García-Aymerich J, Villar J, Ramírez-Sarmiento A, Anto JM, Gea J. Wood smoke exposure and risk of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(3):542-546.
4. López-Campos JL, Fernández-Villar A, Calero-Acuña C, et al; On-Sint Study Investigators. Occupational and biomass exposure in chronic obstructive pulmonary disease: results of a cross-sectional analysis of the On-Sint study. Arch Bronconeumol. 2017;53:7-12.
5. Ramírez-Venegas A, Sansores RH, Quintana-Carrillo RH, et al. FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure. Am J Respir Crit Care Med. 2014;190(9): 996-1002.
6. Camp PG, Ramírez-Venegas A, Sansores RH, et al. COPD phenotypes in biomass smokeversus tobacco smoke-exposed Mexican women. Eur Respir J. 2014;43(3):725-734.
7. Mehra D, Geraghty PM, Hardigan AA, Foronjy R. A comparison of the inflammatory and proteolytic effects of dung biomass and cigarette smoke exposure in the lung. PLoS One. 2012;7(12):e52889.
8. Solleiro-Villavicencio H, Quintana-Carrillo R, Falfán-Valencia R, Vargas-Rojas MI. Chronic obstructive pulmonary disease induced by exposure to biomass smoke is associated with a Th2 cytokine production profile. Clin Immunol. 2015;161(2):150-155.
9. Golpe R, Sanjuán-López P, Cano-Jiménez E, Castro-Añón O, Pérez-de-Llano LA. Distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke. Arch Bronconeumol. 2014;50:318-324.
10. Celli BR, Locantore N, Yates J, et al; ECLIPSE Investigators. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10): 1065-1072.
11. Global Initiative for Chronic Obstructive Lung Disease (GOLD) [homepage on the Internet]. Global Strategy for the Diagnosis, Management and Prevention of COPD 2017. Available from: http://goldcopd.org/. Accessed June 12, 2017.
12. García-Río F, Calle M, Burgos F, et al. Normativa SEPAR. Espirometría. Arch Bronconeumol. 2013;49:388-401.
13. Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006; 61(1):23-28.
14. Vargas-Rojas MI, Solleiro-Villavicencio H, Ramírez-Venegas A, Velázquez-Uncal M, Quintana R, Sansores-Martínez R. Differences in the polarization of the inflammatory response of patients with chronic obstructive pulmonary disease (COPD) secondary to smoking and to biomass smoke exposure. Eur Respir J. 2013;42(Suppl 57):595.
15. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;370:797-799.
16. Montaño M, Sansores RH, Becerril C, et al. FEV1 inversely correlates with metalloproteinases 1, 7, 9 and CRP in COPD by biomass smoke exposure. Respir Res. 2014;15:74.
17. Liu Y, Berthier-Schaad Y, Fallin MD, et al. IL-6 haplotypes, inflammation and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol. 2006;17:863-870.
18. Van Fleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728-735.
19. Apostolakis S, Vogiatzi K, Amanatidou V, Spanidos DA. Interleukin 8 and cardiovascular disease. Cardiovasc Res. 2009;84(3):353-360.
20. Golpe R, Martín-Robles I, Sanjuán-López P, et al. Prevalence of major comorbidities in chronic obstructive pulmonary disease caused by biomass smoke or tobacco. Respiration. 2017;94(1):38-44.
21. Grumelli S, Corry DB, Song LZ, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med. 2004;1(1):e8.
22. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med. 2012;18(5):673-683.
23. Vargas-Rojas MI, Ramírez-Venegas A, Limón-Camacho L, Ochoa L, Hernández-Zenteno R, Sansores RH. Increase of Th17 cells in peripheral blood of patients with chronic obstructive pulmonary disease. Respir Med. 2011;105(11):1648-1654.
24. Di Stefano A, Caramori G, Gnemmi I, et al. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol. 2009;157(2): 316-324.
25. De Torres JP, Casanova C, Hernández C, Abreu J, Aguirre-Jaime A, Celli BR. Gender and COPD in patients attending a pulmonary clinic. Chest. 2005;128(4):2012-2016.
26. Hong Y, Ji W, An S, Han SS, Lee SJ, Kim WJ. Sex differences of COPD phenotypes in nonsmoking patients. Int J Chron Obstruct Pulmon Dis. 2016;11:1657-1662.
27. Faner R, González N, Cruz T, Graciela-Kalko S, Agustí A. Systemic inflammatory response to smoking in chronic obstructive pulmonary disease: evidence of a gender effect. PLoS One. 2014;9(5):e97491.
28. Sussan TE, Ingole V, Kim JH, et al. Source of biomass cooking fuel determines pulmonary response to household air pollution. Am J Respir Cell Mol Biol. 2014;50(3):538-548.
29. Khurana S, Ravi A, Sutula J, et al. Clinical characteristics and airway inflammation profile of COPD persistent sputum producers. Respir Med. 2014;108(12):1761-1770.
30. Röpcke S, Holz O, Lauer G, et al. Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum and induced sputum. PLoS One. 2012;7(10):e46207.
31. Núñez B, Sauleda J, Garcia-Aymerich J, et al; Miembros del Grupo de Trabajo sobre la Caracterización Fenotípica y Evolución de la EPOC (PAC-COPD). Lack of correlation between pulmonary and systemic inflammation markers in patients with chronic obstructive pulmonary disease: a simultaneous, two-compartmental analysis. Arch Bronconeumol. 2016;52:361-367.
32. Akiki Z, Fakih D, Jounblat R, et al. Surfactant protein D, a clinical biomarker for chronic obstructive pulmonary disease with excellent discriminant values. Exp Ther Med. 2016;11(3):723-730.
33. Agustí A, Edwards LD, Rennard SI, et al; Evaluation of COPD longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012; 7(5):e37483.
34. Eisner MD, Anthonisen N, Coultas D, et al; on behalf of the Environmental and Occupational Health Assembly Committee on Nonsmoking COPD. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(5): 693-718